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cause is verifiable. IBS affects 15-20 % of the population, with a highly increasing 60 tendency in industrial nations (2, 3, 4) . The pathophysiology of IBS is yet only partly 61 understood. Recent research suggests that an imbalance of the intestinal microbiota 62 with a significant reduction of bifidobacteria and a dysfunctional intestinal barrier with 63 subsequent bacterial translocation may contribute to the development of IBS and its 64 symptoms (5, 6, 7, 8, 9) . 65
As probiotics have been reported in several studies to restore the intestinal 66 microbiota and gut barrier as well as hinder bacterial translocation, the therapeutic 67 potential of probiotics in IBS has become of strong interest (10, 11) . However the 68 efficacy of probiotics is strongly strain specific and only certain strains might be able 69 to improve IBS and its symptoms (12, 13, 14) . The ability of specific strains to adhere 70 well to intestinal cells may play a pivotal role in altering the intestinal microbiota and 71 increasing the intestinal barrier, which might be of significant value especially in the 72 treatment of IBS. Guglielmetti et al. were able to show in a Caco-2 cell line that the 73 adherence of B. bifidum MIMBb75, which was isolated from a fecal sample of a 74 healthy adult, was significantly better than that of well-studied commercial probiotics 75 (15, 16 This study was performed as a prospective, multi-center, randomized, double-blind, 99 placebo-controlled, two-arm nutritional study. 100
Throughout the study, patients recorded their global IBS symptoms on a daily basis 101 as well as individual IBS symptoms using a patient diary. Additionally, patients have 102 been questioned at a physician site for IBS symptoms (visit 2-4) and quality of life 103 (visit 3 and 4). 104
Physician visits took place at screening, after two weeks (run-in phase), after 6 105 weeks (end of treatment) and after 8 weeks (end of wash-out phase) (Figure 1) . 106 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   5 After the patients have given their written informed consent, they qualified for the 108 screening examination on day 1 (visit 1), which included a complete medical history 109 and physical examination. A blood sample was taken for analysis in a central 110 laboratory, including a pregnancy test. At the screening visit patients were instructed 111 to maintain their eating and life style habits throughout the study. A patient diary was 112 handed out. 113
At the second visit (day 15) diaries were reviewed. Patients who had at least 2 days 114 with mild to moderate pain during the second week of run-in and who fulfilled all 115 inclusion criteria and who did not violate any of the exclusion criteria were 1:1 116 randomized to receive either B. bifidum MIMBb75 or placebo. The treatment was 117 allocated according to a computer-generated blocked randomization list with a block 118 size of 4. The block size was not disclosed to the investigators. During the 119 intervention period, patients received either one probiotic capsule daily over a 4 week 120 period or an identical appearing placebo. The allocation was blinded to both patients 121 and site staff. 122
At the end of the treatment phase (visit 3, day 43), investigators collected the unused 123 study product and empty sachets in order to confirm compliance. Diaries were 124 collected and reviewed. 125
After the nutritional supplement-free wash-out phase (visit 4, day 57), a complete 126 physical examination was performed and a blood sample was taken. 127
Bisacodyl and Loperamid were allowed as rescue medication. Other probiotics and 128 medications that might influence the efficacy of the study product were not allowed. 129 130
Probiotic Preparation 131
Bifidobacterium bifidum MIMBb75 was isolated from the fecal sample of a healthy 132 adult. Bifidobacterium bifidum is a species that is commonly detected in the feces of 133 ranged from 0 (not at all), 1 (very mild), 2 (mild), 3 (moderate), 4 (strong), 5 (very 160 strong) to 6 (intolerable). 161 Secondary efficacy variables included "abdominal pain/discomfort", 162 "distension/bloating", and "urgency", recorded on the same 7-point Likert scale. The 163 individual symptom scores were additionally combined into a composite symptom 164 score as the arithmetic mean of three individual symptom scores. Furthermore, the 165 number of bowel movements, feeling of incomplete bowel evacuation and intake of 166 other medications were reported daily in the diary. 167
At the end of the treatment and again at the end of the study, physicians questioned 168 the patients regarding the global assessment of efficacy, tolerability as well as 169 digestive disorder ("bowel movement satisfaction"). Efficacy was assessed by the 170 following question: "Please consider how you felt during the 4 week treatment 171 regarding your overall well-being, and symptoms of abdominal discomfort/pain and 172 altered bowel habit. Compared to the way you usually felt before taking the study 173 medication, how would you rate your relief of symptoms during the last 4 weeks?" 174 Possible answers were: "completely relieved (1), considerably relieved (2), somewhat 175 relieved (3), unchanged (4) or worse (5)". Both "completely relieved" and 176 "considerably relieved" were defined as "adequate relief". 177
Health related quality of life was assessed by the use of the SF-12 questionnaire 178 prior to the treatment and at the end of the treatment. 179
Adverse events were recorded throughout the study and the global assessment of 180 tolerability was questioned at physician visit 3 and 4. Laboratory values and vital 181 signs were examined at the screening visit and at the end of the study. 182 183
Statistical methods 184
Sample size estimation 185 imputed by the baseline value for the primary target criterion and these patients were 209 evaluated as non-responders (n=1 during treatment, n=3 during wash-out phase). An 210 additional per protocol analysis was performed for supportive purposes. 211 Descriptive analyses of secondary target criteria were based on available data. 212 A total of 132 patients were included into the study and 122 patients were 226 successfully randomized to receive either placebo (N=62) or B. bifidum MIMBb75 227 (N=60). All randomized patients were analyzed for intent to treat (N=122). One 228 patient with no post randomization visit was excluded from the analysis of adverse 229 events. A total of 103 patients (49 placebo, 54 B. bifidum MIMBb75) were examined 230 as per protocol (Fig. 2) . 231 232
Baseline Characteristics 233
In terms of baseline characteristics, there were no significant differences between the 234 groups. 21.3% were classified as diarrhea-predominant IBS (23.3% in the 235 bifidobacteria group, 19.4% in the placebo group), 19.7% as constipation-236 predominant IBS (15% in the bifidobacteria group, 24.2% in the placebo group) and 237 2.79 in the run in phase to 2.63 in the treatment phase) in the placebo group 250 (p<0.0001) using the 7-point Likert scale. The evaluation of the SGA on a weekly 251 basis showed a significant benefit for patients within the bifidobacteria group for 252 every single week starting the second week of treatment till the end of the study (Fig.  253 3). 254 255
Secondary endpoints 256
Secondary endpoints included changes in IBS symptoms -"pain/discomfort", 257 "distension/ bloating", "urgency", "number of bowel movements" and "feeling of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Fig. 4) . 268 269 The evaluation of the IBS symptoms pain/discomfort and distension/bloating on a 270 weekly basis showed a significant benefit for patients within the bifidobacteria group 271 compared to placebo for every single week beginning the second week of treatment 272 till the end of the study. A significant difference in urgency between the bifidobacteria 273 and the placebo group was shown between week four and six ( Overall responders were defined as patients experiencing an improvement of the 293 average weekly score of at least 1 point on the Likert scale for the primary parameter 294 (SGA of IBS symptoms) in at least two out of the 4 weeks treatment period (50% 295 rule). Abdominal pain responders were defined using the same 50% rule for at least 296 one point average improvement for the assessment of "pain/discomfort". Overall 297 responder rates were 56.7% in the bifidobacteria group and only 21.0% in the 298 placebo group (p=0.0001). The difference between the treatment arms was only a 299 little bit less pronounced when considering only the symptom "pain/discomfort" where 300 responder rates were calculated to be 48.3% in the bifidobacteria and only 24.2% in 301 the placebo group (p=0.008) (Fig. 7) . 302 303 Global efficacy at physician site 304
The overall assessment of efficacy was significantly better in the bifidobacteria group 305 compared to placebo. At the end of treatment 43.3% of the patients in the 306 bifidobacteria group achieved adequate relief compared to only 8.1% in the placebo 307 group (p<0.0001). At the end of the study adequate relief was reported for 46.7% in 308 the bifidobacteria and 11.3% of the patients in the placebo group (p<0.0001; Fig. 8) . 309 310 Health related quality of life 311
The evaluation of the SF12 sum scores showed a significant gain in quality of life 312 within the bifidobacteria group. Physical health sum improved from 47.89 at baseline 313 to 51.80 after treatment in the bifidobacteria group and from 47.33 to only 48.85 in 314 appropriately designed studies (4). Apart from inappropriate study design, in our 354 opinion, these findings could be attributed to the fact that the efficacy of probiotics is 355 strongly strain specific and that only few strains might be able to show efficacy in 356
IBS. 357
No study to date could prove unambiguously the mode of action of probiotics, which 358 can be clearly linked to the improvement of IBS and its symptoms. Several studies 359 have observed altered intestinal microbiota with a significant lack of bifidobacteria 360 (25, 26) and a dysfunctional intestinal barrier in IBS patients. These studies have 361 been supported by the fact that a normalization of the lactulose breath test, which 362 suggests the presence of small intestinal bacterial overgrowth or an increased 363 number of enteric microorganisms, is highly correlated with a significant reduction of 364 IBS symptoms (27). It has been stated that the imbalance of the microbiotic 365 composition may lead to a different fermentation pattern, especially with increased 366 bloating (28, 29) . Additionally, gut mucosal barrier 367 disruption has been proven to be associated with bacterial translocation and 368 inflammatory conditions (4,5,6). It seems likely that only specific strains are able to 369 restore an imbalanced intestinal microbiota and gut barrier, however further research 370 is needed to investigate if the positive effects of B. bifidum MIMBb75 can be 371 attributed to this mode of action. 372
There are several limitations of this study. First of all, the study population was not 373 large enough for a sub-group analysis of IBS subtypes. We could therefore not show 374 whether some IBS-subtypes would benefit more from the consumption of B. bifidum 375 MIMBb75 than others. In order to prove whether some subgroups might benefit 376 more, a larger study might be useful. The study population has mild to moderate IBS 377 symptoms as evidenced by the indicated SGA-baseline values. A further study 378
should be aimed at the examination whether the patients with severe IBS symptoms 379 will profit in the same way as those with mild to moderate symptoms or whether these 380 patients are more refractory to this treatment. 381
Additionally, the duration of the study was perhaps short at 4 weeks. It would be of 382 specific value to explore whether patients benefit more from a longer consumption of 383 B. bifidum MIMBb75. Finally, the observation that patients still benefit during the 384 consumption-free wash-out phase is of significant value and requires further 385 investigation (for longer follow-up). 386
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